Unlike traditional benchtop models, which often simplify cardiac structures, UNSW’s soft robotic heart integrates the valve mechanisms critical for unidirectional blood flow. The mitral valve, modeled as a pair of swinging doors, prevents backward leakage of blood—a function essential for maintaining cardiac efficiency. By incorporating artificial musculature controlled hydraulically, the device mimics the heart’s contraction and twisting, producing motion patterns indistinguishable from actual cardiac function. This nuanced replication enables researchers to simulate pathological states, such as mitral valve prolapse and regurgitation, where valve dysfunction leads to compromised blood flow and heightened risk of heart failure.

Heart failure with preserved ejection fraction (HFpEF) remains an enigmatic and devastating condition, constituting about 50% of all heart failure cases. Characterized by the heart’s reduced capacity to relax and fill properly despite maintained pumping function, HFpEF often coexists with systemic comorbidities like hypertension and diabetes. The UNSW soft robotic model can simulate the hallmark features of HFpEF, including the delayed ventricular filling and increased intracardiac pressures observed in patients. This capability provides clinicians and researchers a powerful tool to investigate HFpEF mechanisms and explore novel therapeutic strategies tailored to this complex syndrome.

The engineering breakthrough underpinning this model lies in its use of flexible silicone membranes and layered soft robotic artificial muscles arranged to replicate the heart’s natural muscle fiber architecture. These hydraulic artificial muscles receive precisely regulated pressure inputs to contract and relax in coordination, enabling the ventricular walls to deform and twist as in a genuine heartbeat. The inner membranes form the heart’s chambers and contain simulated blood, allowing for realistic pumping dynamics with in-and-out flow paths. This biomimetic design elevates the fidelity of cardiac simulations far beyond previous mechanical analogues.

One particularly groundbreaking aspect is the system’s adjustable artificial papillary muscles, which support and regulate the mitral valve. By altering the tension in these muscles, the researchers can precisely recreate valve malfunctions and study their impacts on cardiac mechanics and blood flow. This mechanistic insight is vital, as valve pathologies are a common contributor to heart failure progression. The ability to tune valve behavior in a controlled setting allows device developers to test prosthetics and surgical interventions more effectively before transitioning to animal models or clinical trials.

Validation of the synthetic heart involved extensive testing using ultrasound imaging and invasive measurements of pressure and flow to compare its performance against physiological benchmarks. The results were striking—the artificial heart produced realistic waveforms of pressure and blood flow characteristic of healthy and diseased states alike. Moreover, the model’s compatibility with non-invasive clinical techniques such as echocardiography underscores its potential as a translational research tool, bridging laboratory experiments and patient care.

Beyond modeling disease mechanics, the platform serves as a testing ground for emergent cardiovascular technologies. Demonstrating this, the UNSW team evaluated a novel soft robotic cardiac catheter within the beating model. The catheter could navigate precisely inside the artificial heart, sensing contact with moving anatomic structures. This demonstrated the system’s utility for iterative design and validation of surgical devices, potentially accelerating innovation in minimally invasive cardiac therapies with improved safety profiles.

Ethical concerns and high costs have long hampered preclinical testing relying on animal models, limiting throughput and translational efficiency. The synthetic heart’s controllable and reproducible environment offers a humane and cost-effective alternative for early-stage device evaluation. By faithfully reproducing specific disease phenotypes, such as HFpEF, the technology could reduce dependence on animal testing, accelerating development timelines while preserving scientific rigor.

Looking forward, the researchers envision personalizing these soft robotic hearts using patient-derived medical imaging data. Such bespoke models could inform clinical decision-making by enabling surgeons to trial different interventions in a risk-free setting tailored to each patient’s unique cardiac anatomy and physiology. This aligns perfectly with the burgeoning field of precision medicine, where treatments are customized for maximal efficacy and safety.

While this soft robotic heart represents a significant technological milestone, the team acknowledges that it remains a proof-of-concept rather than a fully clinical device. Future iterations will aim to integrate more sophisticated materials, refine control systems for enhanced realism, and incorporate patient-specific geometric complexities. The crucial next step involves comprehensive validation against a broad spectrum of clinical data to establish the model’s predictive accuracy across diverse cardiac conditions and anatomies.

The integration of expertise from biomedical engineering and clinical cardiology, including collaboration with leading clinicians, underscores the translational potential of this technology. The resulting platform offers a versatile, high-fidelity testbed for advancing cardiovascular research, improving device safety, and ultimately improving patient outcomes. As soft robotics and bioengineering converge, the dream of a truly functional artificial heart model that serves as a clinical decision and treatment tool moves closer to reality.

In conclusion, UNSW’s soft robotic heart blends innovation in materials science, robotics, and clinical insights to create a biomimetic device capable of simulating complex cardiac physiology and pathology with unprecedented accuracy. By enabling detailed study of valve mechanics, heart muscle dynamics, and disease progression, it stands to revolutionize cardiovascular research. More importantly, it paves the way for personalized treatment approaches that could substantially reduce the burden of cardiovascular disease globally, offering new hope to millions suffering from heart failure.

Subject of Research: Not applicable

Article Title: Compliance modulation of a soft robotic atrioventricular model of heart failure with preserved ejection fraction

News Publication Date: 1-Jun-2026

Web References:

• Nature Communications article: https://www.nature.com/articles/s41467-026-73791-w
• Advanced Science article: https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/advs.75382

References:

• UNSW Medical Robotics Lab
• UNSW School of Biomedical Engineering

Image Credits: UNSW/Richard Freeman

Keywords

Cardiovascular disorders, Bioengineering, Biomedical engineering, Heart failure with preserved ejection fraction (HFpEF), Soft robotic heart, Mitral valve disease, Cardiac biomechanics, Medical device development, Patient-specific models, Soft robotics, Cardiovascular research

The endothelial glycocalyx is a complex meshwork of glycoproteins, proteoglycans, and glycosaminoglycans that covers the luminal surface of endothelial cells. It acts as a crucial interface for molecular exchange and mechano-transduction, influencing blood flow, vascular permeability, and inflammatory responses. Despite its importance, direct assessment of endothelial glycocalyx integrity has long posed a challenge due to its delicate nature and inaccessibility through conventional vascular imaging techniques. Prior methods required invasive procedures or indirect markers, which limited clinical utility and resolution.

However, the research conducted by Butler, Ramnath, Crompton, and colleagues illuminates an intricate molecular dialogue occurring at the interface of erythrocytes and the endothelial glycocalyx. Their data demonstrate that specific glycocalyx components undergo dynamic exchange with erythrocyte surfaces under physiological shear flow conditions. This exchange creates a biochemical signature on circulating erythrocytes that reflects the current state of endothelial health. Importantly, these signatures are retrievable through minimally invasive blood draws, enabling a liquid biopsy approach to evaluate endothelial function with unprecedented specificity.

To arrive at these conclusions, the investigative team employed a combination of high-resolution microscopy, flow cytometry, and glycomics profiling, allowing them to characterize the glycocalyx-erythrocyte interaction at both structural and molecular levels. Utilizing advanced labeled probes and antibody arrays, they mapped how key glycocalyx constituents—such as heparan sulfate and chondroitin sulfate—are transiently incorporated onto erythrocyte membranes. This transient coating not only reflects the intactness of the endothelial glycocalyx but also serves as a functional biomarker indicative of vascular health or early pathology.

A particularly innovative aspect of this research is their exploitation of biophysical forces within the circulatory system. Under normal blood flow, the shear stress exerted on endothelial cells modulates the glycocalyx’s conformation and shedding behavior. The erythrocytes, constantly subjected to the same shear forces, serve as dynamic platforms that capture the shedding or remodeling events of the glycocalyx. By decoding this erythrocyte-bound glycocalyx material, the researchers effectively harnessed a living readout of endothelial status. This approach circumvents the need for invasive biopsy or indirect plasma markers that have traditionally limited endothelial diagnostics.

The clinical implications of this work are profound. Endothelial dysfunction precedes and predicts a spectrum of vascular diseases including atherosclerosis, hypertension, and diabetic complications. Early detection through facile liquid biopsies could enable timely therapeutic interventions thereby modifying disease trajectory. Furthermore, serial sampling from patients permits longitudinal monitoring of treatment efficacy or disease progression, an advantage over snapshots provided by conventional imaging or systemic biomarkers.

In terms of technological advancement, the methodology described offers scalability and adaptability. The assay relies on standard blood collection coupled with high-sensitivity detection platforms that can be integrated into existing clinical laboratory workflows. Potential future developments may incorporate point-of-care devices or microfluidic systems designed to isolate and analyze erythrocyte glycocalyx components rapidly, thus broadening applicability in varied healthcare settings.

Moreover, this discovery prompts re-examination of erythrocyte biology beyond oxygen transport. Erythrocytes have conventionally been viewed as passive carriers within the vasculature; however, their capacity to acquire endothelial-derived molecular signatures suggests an active role in vascular health surveillance. This paradigm shift could inspire additional research into how erythrocytes participate in systemic signaling networks and vascular responses.

From a research perspective, the identification of key glycocalyx molecules exchanged with erythrocytes provides a molecular window into endothelial cell-environment interactions. Understanding these molecules’ dynamics under different pathological stimuli, such as inflammation or oxidative stress, may reveal novel therapeutic targets. It may also facilitate the development of stratified treatment algorithms personalized to individual endothelial phenotypes as revealed by liquid biopsy analysis.

This work also highlights interdisciplinary collaboration, merging fields of vascular biology, analytical chemistry, and biomedical engineering. The successful decoding of glycocalyx-erythrocyte interfaces exemplifies how integrative technologies can solve longstanding biomedical problems. It serves as a testament to the power of convergent scientific approaches in achieving breakthroughs with tangible clinical impact.

Despite its promise, further validation in diverse patient populations and pathological conditions will be essential. Establishing standardized reference ranges and understanding potential confounding variables such as erythrocyte lifespan or systemic metabolic factors will refine assay accuracy. Moreover, longitudinal studies will be needed to confirm predictive value in chronic vascular diseases and to determine responsiveness to therapies targeting endothelial restoration.

In sum, the elucidation of endothelial-erythrocyte glycocalyx exchange represents a transformative step forward in vascular medicine. The prospect of liquid biopsies that capture real-time endothelial function could revolutionize disease diagnosis, monitoring, and individualized treatment paradigms. As science continues to unravel the molecular intricacies of this novel biomarker interface, patients stand to benefit profoundly from earlier interventions and precision vascular care.

This pioneering research published in Nature Communications underscores a future where the complexities of vascular biology are accessible through simple blood tests. The translation from bench to bedside envisions a new era in cardiovascular health management, where technology meets biology to deliver unmatched insights into endothelial integrity.

Continued exploration of this innovative liquid biopsy platform promises to redefine vascular diagnostics and expand understanding of how blood cells and vessel walls intimately communicate to sustain circulatory health. The interdisciplinary methodology and striking clinical potential make this a landmark study with the capacity to generate significant scientific and societal impact.

Subject of Research: Endothelial function and glycocalyx-erythrocyte interactions enabling liquid biopsies

Article Title: Endothelial-erythrocyte glycocalyx exchange enables liquid biopsies of endothelial function

Article References:
Butler, M.J., Ramnath, R.R., Crompton, M. et al. Endothelial-erythrocyte glycocalyx exchange enables liquid biopsies of endothelial function. Nat Commun 17, 3568 (2026). https://doi.org/10.1038/s41467-026-71848-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-026-71848-4

Carotid Angiography, a widely used imaging technology, offers detailed visualizations of blood vessels in the head and neck. Coupled with the high-resolution imaging capability of OCT, physicians can gain crucial insights into the structural and functional aspects of arterial walls. However, aligning these different imaging techniques has traditionally posed a considerable challenge. The advent of machine learning algorithms provides a way to overcome the limitations of manual co-registration, enhancing both accuracy and efficiency of the combined imaging approach.

The research presented by Xu et al. delves deeper into this revolutionary method, elaborating on the algorithms implemented to automate the co-registration process. By leveraging deep learning techniques, the researchers trained their models on a substantial dataset, enabling the algorithm to learn the complexities of different imaging modalities. The results reveal an impressive ability of the machine learning models to accurately align the images, demonstrating higher fidelity than conventional methods.

In clinical settings, the ability to seamlessly integrate these images could lead to better diagnosis and monitoring of cardiovascular diseases. Carotid artery disease, for instance, is a significant contributor to stroke, making accurate assessment critical. The newly developed automated image registration can potentially facilitate longitudinal assessments of disease progression or treatment efficacy, enriching the patient care pathway.

The study also highlights the methodological rigor employed in validating the effectiveness of the machine learning approach. The researchers utilized quantitative performance metrics to evaluate the accuracy and reliability of the co-registered images. This rigorous validation process not only underscores the robustness of their findings but also holds promise for broader applications in medical imaging beyond just carotid studies.

While the findings exhibit considerable potential, the authors also acknowledge the limitations of the pilot study. For instance, the sample size was relatively small, meaning that further research with larger cohorts is necessary to confirm these initial results. Additionally, the complexity of biological systems may pose additional challenges in diverse patient populations, particularly with varying anatomical features that may require fine-tuning of the model.

Despite these challenges, the implications of this research are far-reaching. The automatic co-registration technique can significantly reduce the time clinicians spend on image preparation, allowing them to focus on interpretation and decision-making regarding patient care. Moreover, this innovation aligns with a broader trend in medicine — the increasing reliance on artificial intelligence and machine learning to enhance clinical practices.

Moreover, the automatic nature of this process could lower the barrier to entry for smaller medical facilities that may lack access to expensive imaging software capable of performing manual alignments. By democratizing accessibility to advanced cross-sectional imaging analyses, the study holds the promise of improving health outcomes on a wider scale, particularly in underserved regions.

As the study underscores the mounting evidence in favor of adopting machine learning solutions, it also fuels the ongoing discussion around the regulatory and ethical frameworks necessary for integrating AI in healthcare. Due to the profound implications for patient care, incorporating AI in medical systems must be handled with utmost caution, ensuring that the technology is not only effective but also safe for patients.

Looking forward, the researchers express a desire to continue refining their algorithms and expanding the scope of their studies. They envision future applications wherein the co-registration technique could be adapted to other vascular regions or even different organ systems altogether, allowing for further exploration of the intricate relationships between structure and function in human health.

In conclusion, Xu et al.’s pioneering work encapsulates the essence of modern healthcare innovation — maximizing the potential of technology to enhance diagnostic practices. As we embrace this era of machine intelligence in medicine, studies like these pave the path for improved integration of diagnostic imaging, thereby transforming how clinicians approach complex cardiovascular conditions.

Harnessing the power of machine learning for automated image registration not only enhances current clinical practices but also opens avenues for future research aimed at unveiling new truths about human health and disease. As researchers continue to innovate, we anticipate a future where such technological advancements become standard practice, revolutionizing patient care.

As the worlds of technology and medicine converge, we remain optimistic about what lies ahead, as each new study brings us one step closer to realizing the full potential of artificial intelligence in enhancing human health.

Subject of Research: Automatic image co-registration using machine learning techniques in conjunction with Carotid Angiography and Intravascular Optical Coherence Tomography.

Article Title: Automatic Image Co-registration of Carotid Angiography and Intravascular Optical Coherence Tomography Based on Machine Learning Method: A Pilot Feasibility Study.

Article References:

Xu, H., Li, JN., Xu, Y. et al. Automatic Image Co-registration of Carotid Angiography and Intravascular Optical Coherence Tomography Based on Machine Learning Method: A Pilot Feasibility Study.
Ann Biomed Eng (2025). https://doi.org/10.1007/s10439-025-03872-2

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10439-025-03872-2

Keywords: Machine Learning, Image Co-registration, Carotid Angiography, Intravascular Optical Coherence Tomography, Cardiovascular Imaging.

Central venous pressure is a fundamental clinical parameter that reflects the pressure within the thoracic vena cava near the right atrium of the heart. It is indispensable in managing critical conditions such as heart failure, sepsis, and various circulatory disorders. Historically, CVP measurements required the insertion of catheters into central veins—a method both invasive and fraught with potential complications such as infection, thrombosis, and mechanical injury. Noninvasive alternatives have existed, including jugular venous pulsation (JVP) assessment, but these have been impeded by operator dependency and inconsistent accuracy. Enter the QCU method, a breakthrough that quantifies the mechanical response of the internal jugular vein (IJV) under controlled compression, enabling precise and reproducible CVP estimation without breaching the skin.

The study enrolled eleven patients from the cardiac intensive care unit at MGH, all equipped with central venous catheters as part of their routine clinical care. This provided a unique opportunity for the researchers to juxtapose the novel ultrasound-derived measurements against the gold-standard invasive CVP readings. During the procedure, researchers utilized short-axis ultrasound imaging to capture cross-sectional views of the IJV. Crucially, simultaneous real-time measurements of the force applied to the skin surface via the ultrasound probe were recorded. This dual data acquisition allowed the team to meticulously analyze the relationship between externally applied compression force and the mechanical behavior of the IJV—a vessel whose collapse under pressure reflects the internal venous pressure.

A critical facet of this technique is the determination of the collapse force (CF): the precise force required to entirely occlude the internal jugular vein’s lumen in its short-axis view. This parameter emerged as a robust predictor of CVP. Applying advanced statistical techniques, notably linear regression analysis, the research team demonstrated a strong positive correlation between CF and invasively measured CVP values, with an impressive coefficient of determination (r²) of 0.82. The mean absolute error of 1.08 mmHg further underscored the method’s accuracy. Interestingly, when accounting for hydrostatic pressure offsets—factors such as patient positioning and gravitational influence—the correlation slightly improved to an r² of 0.83, indicating consistent reliability in varied clinical scenarios.

In contrast, jugular venous pulsation height (JVP), a conventional and widely utilized noninvasive marker, exhibited a substantially weaker correlation with invasive CVP. The linear regression for JVP yielded an r² of only 0.45 and a higher mean absolute error of 1.39 mmHg, underscoring intrinsic limitations linked to subjective measurement variability and patient-specific anatomical factors. The compelling superiority of the QCU approach over JVP offers a powerful incentive for reconsidering noninvasive hemodynamic monitoring protocols in clinical practice.

At its core, quantitative compression ultrasound leverages high-resolution imaging coupled with precise force quantification to create an inverse mechanical model of venous function. By applying incremental external force through the ultrasound probe and measuring the vessel’s cross-sectional area response, clinicians gain insight into venous compliance and transmural pressure. This methodology effectively translates ultrasound image segmentation and biomechanical modeling into a clinically actionable metric—central venous pressure—that guides critical therapeutic decisions, such as fluid management and vasopressor titration.

The clinical implications of this groundbreaking technology are profound. Noninvasive, reliable CVP measurement could dramatically shift treatment paradigms, especially in settings where invasive catheter placement is contraindicated or logistically unfeasible. In resource-limited environments, this innovation could democratize access to vital hemodynamic monitoring, reducing dependence on specialized personnel and complicated equipment. Furthermore, routine and frequent monitoring enabled by the QCU method may enhance patient safety by facilitating early detection of hemodynamic deterioration without subjecting patients to procedural risks.

Methodologically, this pilot study showcased meticulous design incorporating cross-disciplinary expertise from electrical engineering, mechanical engineering, and cardiology. Researchers developed sophisticated QCU data acquisition protocols, ensuring synchronized recording of ultrasound imagery and mechanical force metrics. The segmentation of carotid artery and internal jugular vein images in their compressed and uncompressed states provided a rich dataset for biomechanical modeling. The involvement of experienced clinicians in correlating these measurements with invasive CVP readings ensured clinical relevance and data robustness.

The success of this study also shines a light on the growing trend of integrating engineering and medicine to develop innovative diagnostic tools. The team, led by Brian W. Anthony along with collaborators from MIT and MGH, exemplifies the power of interdisciplinary research in translating benchside technology to bedside application. By harnessing principles of fluid mechanics, biomechanics, and advanced imaging, their work bridges the gap between theoretical modeling and real-world clinical utility.

Looking forward, scalability and automation of the QCU technique present exciting avenues for development. Machine learning algorithms could enhance image segmentation accuracy and reduce operator dependency further. Integration with portable ultrasound devices may facilitate bedside or even home-based monitoring, opening the door to personalized cardiovascular care. The potential for seamless integration with other noninvasive monitoring modalities, such as photoplethysmography or pulse wave velocity estimation, could culminate in comprehensive, multimodal hemodynamic assessment platforms.

This clinical pilot study represents a landmark achievement, affirming that noninvasive measurements derived from the mechanics of venous collapse can serve as a reliable proxy for direct CVP assessment. It challenges longstanding clinical dogmas and offers a roadmap for safer, more conventional cardiovascular monitoring approaches. In doing so, it elevates quantitative compression ultrasound from a promising research concept to a validated clinical instrument with tangible patient benefits.

As healthcare seeks technological solutions that enhance accuracy, reduce invasiveness, and improve patient experience, this pioneering work serves as a testament to innovation’s transformative impact. The path forward includes larger cohort validation, real-world clinical trials, and exploration of applications across diverse patient populations—objectives that the MIT and MGH research teams are well poised to pursue.

In sum, the development of QCU-based CVP measurement heralds a new era in hemodynamic monitoring. By converting precise biomechanical data into actionable clinical information without the need for invasive catheters, this technology offers a crucial lifeline for patients and clinicians alike. Noninvasive, reliable, and efficient—the future of cardiovascular diagnostics is here, bringing with it hope for improved outcomes, streamlined workflows, and enhanced patient safety worldwide.

Subject of Research: Noninvasive measurement of central venous pressure using quantitative compression ultrasound.

Article Title: Noninvasive Quantitative Compression Ultrasound Central Venous Pressure: A Clinical Pilot Study.

News Publication Date: 19-Mar-2025.

Web References: http://dx.doi.org/10.34133/bmef.0115

Image Credits: Anthony Lab@MIT.

Keywords: Health and medicine; Clinical medicine; Cardiovascular disease.